Description: Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Home Page: www.karyopharm.com
85 Wells Avenue
Newton,
MA
02459-3298
United States
Phone:
617 658 0600
Officers
| Name | Title |
|---|---|
| Mr. Richard A. Paulson M.B.A. | President, CEO & Director |
| Ms. Sohanya Cheng M.B.A. | Executive VP, Chief Commercial Officer & Head of Business Development |
| Mr. Stuart Poulton | Executive VP & Chief Development Officer |
| Dr. Reshma Rangwala M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Research |
| Dr. Mansoor Raza Mirza M.D. | Clinical Consultant, Member of Scientific Advisory Board & Independent Director |
| Dr. Sharon Shacham M.B.A., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Ms. Kristin Abate | VP, Chief Accounting Officer, Interim Principal Financial Officer & Assistant Treasurer |
| Mr. Michael J. Mano J.D. | Senior VP, General Counsel & Secretary |
| Mr. James Accumanno J.D. | Chief Compliance Officer |
| Ms. Sarah Connors | Vice President of Corporate Communications |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 12.7118 |
| Price-to-Sales TTM: | 0.6396 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 325 |